MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.

Leave a Comment / CHC / By

Vitellius C, Desjonqueres E, Lequoy M, Amaddeo G, Fouchard I, N’Kontchou G, Canivet CM, Ziol M, Regnault H, Lannes A, Oberti F, Boursier J, Ganne-Carrie N.JHEP Rep. 2024 Jun 29;6(10):101160. doi: 10.1016/j.jhepr.2024.101160. eCollection 2024 Oct.PMID: 39411648  Abstract Background & aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers …

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis. Read More »

EASL position paper on clinical follow-up after HCV cure.

Leave a Comment / CHC, Cirrhose / By

Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, Elsharkawy AM, Forns X.J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6.PMID: 38845253 Review. Abstract Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding …

EASL position paper on clinical follow-up after HCV cure. Read More »

Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board.

Leave a Comment / Non classé / By

Nault JC, Calderaro J, Ronot M.J Hepatol. 2024 Oct;81(4):756-762. doi: 10.1016/j.jhep.2024.05.041. Epub 2024 Jun 11.PMID: 38871125 Abstract Primary liver tumours, including benign liver tumours, hepatocellular carcinoma and cholangiocarcinoma, present a multifaceted challenge, necessitating a collaborative approach, as evidenced by the role of the multidisciplinary tumour board (MDTB). The approach to managing primary liver tumours involves specialised …

Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board. Read More »

Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.

Leave a Comment / Cholangiocarcinome / By

Alitti C, Rode A, Trillaud H, Merle P, Blanc JF, Blaise L, Demory A, Nkontchou G, Grando V, Ziol M, Nahon P, Ganne-Carrié N, Petit A, Seror O, Sutter O, Nault JC.Liver Int. 2024 Jun;44(6):1363-1372. doi: 10.1111/liv.15886. Epub 2024 Mar 4.PMID: 38436538 Abstract Introduction: The effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied. …

Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma. Read More »

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence.

Leave a Comment / CHC / By

Boros C, Sutter O, Cauchy F, Ganne-Carrié N, Nahon P, N’kontchou G, Ziol M, Grando V, Demory A, Blaise L, Dondero F, Durand F, Soubrane O, Lesurtel M, Laurent A, Seror O, Nault JC.Liver Int. 2024 Jun;44(6):1464-1473. doi: 10.1111/liv.15900. Epub 2024 Apr 6.PMID: 38581233 Abstract Introduction: We aim to assess the long-term outcomes of percutaneous multi-bipolar radiofrequency (mbpRFA) …

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence. Read More »

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Leave a Comment / CHC / By

Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, Noblet B, Nahon P, Hormigos K, Sidali S, Seror O, Taly V, Ganne Carrie N, Laurent-Puig P, Zucman-Rossi J, Nault JC.Gut. 2024 Oct 7;73(11):1870-1882. doi: 10.1136/gutjnl-2024-331956.PMID: 39054058 Abstract Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic …

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Read More »

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

CHC / By

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC.J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.PMID: 37647991 Background & aims: The “French Medicine Genomic program 2025” has been designed to give patients with cancers …

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Read More »

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

CHC / By

Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. J Hepatol. 2023 Mar;78(3):584-595. doi: 10.1016/j.jhep.2022.11.003. Background & aims: Identifying individuals at higher risk of developing hepatocellular carcinoma (HCC) is pivotal to improve the performance …

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis Read More »

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis

CHC, Cirrhose / By

Nahon P, Layese R, Ganne-Carrié N, Moins C, N’Kontchou G, Chaffaut C, Ronot M, Audureau E, Durand-Zaleski I, Natella PA; ANRS CO12 CirVir and CIRRAL groups. Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615. Background and aims: Hepatocellular carcinoma (HCC) surveillance is challenged by the detection of hepatic focal lesions (HFLs) of other types. This study aimed …

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis Read More »

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

Cirrhose / By

Louvet A, Bourcier V, Archambeaud I, d’Alteroche L, Chaffaut C, Oberti F, Moreno C, Roulot D, Dao T, Moirand R, Duclos-Vallée JC, Goria O, Nguyen-Khac E, Pol S, Carbonell N, Gournay J, Elkrief L, Fouchard-Hubert I, Chevret S, Ganne-Carrié N; CIRRAL group. J Hepatol. 2023 Mar;78(3):501-512. doi: 10.1016/j.jhep.2022.11.013. Epub 2022 Nov 22. Background & aims: …

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort Read More »